stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) Revenue
Regeneron Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $14.3B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $16.9B. Over the past ten years it has ranged from $4.1B (fiscal 2015) to $16.1B (fiscal 2021); the current reading is higher than 91% of that period. Revenue has risen for 3 consecutive fiscal years. Regeneron Pharmaceuticals, Inc. ranks 1st of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $14.3B | 0.99% |
| FY2024 | $14.2B | 8.27% |
| FY2023 | $13.1B | 7.76% |
| FY2022 | $12.2B | (24.26%) |
| FY2021 | $16.1B | 89.14% |
| FY2020 | $8.5B | 29.58% |
| FY2019 | $6.6B | 27.44% |
| FY2018 | $5.1B | (12.37%) |
| FY2017 | $5.9B | 20.82% |
| FY2016 | $4.9B | 18.44% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $5.1B | 19.23% |
| Jun 2026 | $4.3B | 19.01% |
| Mar 2026 | $3.6B | (7.18%) |
| Dec 2025 | $3.9B | 3.46% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $16.9B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $13.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.6B |
| ARGX argenex SE compare | $5.9B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| RPRX Royalty Pharma PLC compare | $2.6B |
| MRNA Moderna, Inc. compare | $2.2B |
| RVMD Revolution Medicines, Inc. compare | $209.1M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on REGN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement